Clinical Differentiation of Self-Limited Epilepsy With Autonomic Seizures (Panayiotopoulos Syndrome) and Childhood Migraine Authors: Eva Berg, Niels K.N. Focke, Knut Brockmann Published: 2026 ABSTRACT Background and ObjectivesMigraine is the most common single cause of health loss among children and adolescents. A specific type of pediatric benign focal epilepsy, i.e., self-limited epilepsy with autonomic seizures (SeLEAS), formerly called Panayiotopoulos syndrome, is often accompanied by ictal or postictal headache, which can sometimes be indistinguishable from migraine. To date, no studies have provided estimates of the proportion of misdiagnoses in this context. This study aimed to assess the proportion of pediatric patients labeled as having “migraine” or “headache” who actually have SeLEAS.MethodsA retrospective review was conducted of EEG findings and physicians' letters from 186 patients aged 3 to 14 years, referred over a 2-year period to a tertiary care university hospital's pediatric neurology department for “migraine” or “headache.”ResultsBased on clinical history, EEG results, and the clear efficacy of antiseizure medication (ASM), 6.5% (n = 12) of the children were ultimately diagnosed with SeLEAS. An additional 3 patients showed no improvement with pharmacotherapy using only 1 antiseizure substance. Furthermore, 12.4% (n = 23) of children and adolescents presenting with headache attacks met the clinical and EEG criteria for SeLEAS but did not receive ASM. Reasons included that the diagnosis was not recognized during consultation (n = 16) or that medication was either not recommended by the physician or not initiated by the family (n = 4). In total, 18.8% (n = 35) of pediatric patients initially diagnosed with “migraine” or “headache” received a possible, probable, or definite diagnosis of benign focal epilepsy with autonomic seizures.DiscussionWhen evaluating children and adolescents with headache, clinicians should give greater consideration to SeLEAS as a differential diagnosis than in the past, especially due to its significant therapeutic implications. Introduction The recent update of the Global Burden of Disease study (GBD) published in March 2024 identified migraine as the most common single cause of health loss in terms of disability-adjusted life-years (DALYs) among children and adolescents aged 5 to 19 years.1,2 The clinical features of migraine, as defined by the International Headache Society, and the specific characteristics of migraine in children and adolescents are well known: primarily, migraine without aura involves headache along with nausea and/or photophobia and phonophobia.3,4 For children and adolescents aged 5 to 19 years, 380.0 [24.7–946.6] DALYs per 100,000 people were estimated to be caused by migraine.1 DALYs are equal to years lived with disability (YLDs) for conditions to which no deaths are ascribed, such as headaches including migraine.1 According to the Population Reference Bureau (PRB),5 approximately 2 billion children and adolescents younger than 15 years are living currently worldwide. As these age ranges used by GBD and PRB differ, if we assume only 200 (instead of 380) DALYs, i.e., YLDs due to migraine, misdiagnosis of migraine in only 1% of children and adolescents aged 5 to 14 years would attribute to 40,000 YLDs worldwide. These figures may reveal the magnitude of the problem of possible systematic misdiagnosis in childhood migraine. Early on, it was emphasized that a particular type of pediatric benign focal epilepsy, known as self-limited epilepsy with autonomic seizures (SeLEAS), formerly called Panayiotopoulos syndrome, is often accompanied by ictal or postictal headache, which can sometimes be indistinguishable from migraine.6-11 SeLEAS was first described by Chrystosomos P. Panayiotopoulos in a series of publications, initially named “benign childhood epilepsy with occipital paroxysms,”12 later called “early-onset benign occipital seizure susceptibility syndrome (early-onset benign occipital seizure susceptibility syndrome)”,7 and more recently referred to as Panayiotopoulos syndrome. The 2022 classification and definition of epilepsy syndromes with childhood onset by the International League Against Epilepsy (ILAE) renamed this condition “self-limited epilepsy with autonomic seizures (SeLEAS).”13 Panayiotopoulos8 described the main features of EBOSS: rare (often single) focal seizures that initially present with gaze deviation and vomiting, sometimes progressing to hemiplegic or generalized convulsions.7,8 Behavioral changes during seizures, irritability, pallor, cyanosis, and wide-open eyes are common. Other manifestations may include choking, coughing, oro-pharyngo-laryngeal movements, incontinence, and impaired or lost consciousness, which can be either initial or secondary during prolonged seizures. Seizure duration varies from a few minutes to hours, often occurring at night during sleep, although semiology is similar in both nocturnal and diurnal seizures.7,8 The recent renaming to “self-limited epilepsy with autonomic seizures” highlights the frequent autonomic features during ictal episodes. According to Specchio et al.,13 these autonomic features may vary at onset, “but most frequently include retching, pallor, flushing, nausea, malaise, or abdominal pain. Vomiting, the most common autonomic manifestation, occurs in approximately 75% of children and leads to misdiagnosis of acute gastroenteritis or migraine. Additional autonomic features include pupillary (e.g., mydriasis), temperature, and cardiorespiratory (breathing, pallor, cyanosis, and heart rate) changes. Syncope may rarely occur.” Reports on headache occurrence during SeLEAS attacks vary widely, from 4.6% to 55%.14,15 Seizures typically begin between ages 1 and 14 years, peaking between 3 and 6 years, with an excellent prognosis.12,14 Early reports focusing on this classical semiology suggested a low seizure frequency and a limited total number of seizures, with one-third of children experiencing only a single seizure and an average of 2 to 3 seizures overall.12,14 The likelihood of additional SeLEAS-typical seizures after the age of 14 years is very low.8 Among the self-limited epilepsies of childhood, SeLEAS is the second most prevalent, after self-limited epilepsy with centrotemporal spikes (SeLECTS, benign Rolandic epilepsy). SeLEAS is considered to account for 5% of childhood epilepsies between 1 and 14 years.13 Electroencephalography (EEG) may reveal occipital paroxysms with fixation-off sensitivity. However, findings can vary, and EEGs may also show random occipital spikes, occipital spikes during sleep, or even appear normal.8,14 In addition, centrotemporal and other spike foci may be present either in the same EEG or, more frequently, in subsequent recordings.8 Importantly, the interictal EEG findings do not necessarily correlate with the clinical course or severity of the epilepsy.7,8,16 Based on previous studies and our clinical experience, differentiating SeLEAS from classic or atypical migraine can be challenging.8,17-21 In some cases, this distinction cannot be made with certainty based solely on medical history and clinical findings.10,22 Accurate diagnosis is crucial, as it has significant therapeutic implications. This raises the question, how many pediatric patients with SeLEAS and an ambiguous clinical presentation are misdiagnosed as having migraine. A PubMed search did not reveal any studies specifically addressing this issue. Objective of This Study This single-center, observational, retrospective study aimed to determine the proportion of pediatric patients who were referred with a diagnosis of “migraine” or “headache” at a tertiary care university hospital's pediatric neurology department but ultimately received a final diagnosis of benign focal epilepsy, specifically SeLEAS. In addition, the study sought to compare the symptoms reported by patients and their parents during migraine attacks with those observed during cerebral seizures associated with SeLEAS. The goal was to identify potential clinical features that could help differentiate these 2 conditions more accurately based on their semiology. Methods This retrospective study evaluated EEG findings and physicians' letters of patients aged 3 to 14 years who were referred to the Pediatric Neurology Consultation at the Department of Pediatrics and Adolescent Medicine, University Medical Center Göttingen, Germany, during 2019 and 2020. These patients were referred by their general practitioners or pediatricians with the initial diagnosis of “migraine” or “headache.” The Pediatric Neurology Consultation is provided on a rotational basis by junior doctors (specialists or doctors in training) under the supervision of an experienced senior physician. As part of their initial assessment, patients routinely undergo an EEG, which is documented in the EEG laboratory records, including the clinical indication of “migraine” or “headache.” This procedure reflects a local routine practice. We are aware that this approach is not in accordance with international guidelines on assessment of headache in childhood. However, it is due to certain organizational processes: Already years ago we had occasionally encountered children with migraine-like attacks who in fact had SeLEAS. Therefore, we implemented EEG in the diagnostic procedure in ambiguous phenotypes. When parents make an appointment for their child, the administrative staff at the departmental control center provides the combination of an EEG and an appointment in the pediatric neurology consultation hours, with the EEG being recorded first. During the phone call, administrative staff cannot reliably distinguish between a “migraine” with an ambiguous phenotype and another type of headache. Therefore, we always schedule an EEG appointment in advance as in most cases, it is not possible to perform an ad hoc EEG. As it turned out, this routine practice enabled us to perform this retrospective study. Data collected included age at first presentation and sex. The physicians' letters from the consultations, stored in the hospital's digital archive, were then reviewed. The following information was extracted: The number of patients who received a definite or possible diagnosis of SeLEAS during their initial visit. Among these, how many had an indication for antiseizure medication (ASM), based on seizure frequency and severity causing significant distress. How many of these patients received ASM with the consent of the child and parents. How many attended follow-up appointments in pediatric neurology. Among those, how many experienced an improvement in headache attacks after ASM, supporting the diagnosis of SeLEAS. EEG findings were classified as:“(Multi)focal interictal epileptiform discharges (IEDs)”,“IEDs plus focal slowing” and “Normal” (including vigilance-related slowing or physiologic EEG). “(Multi)focal interictal epileptiform discharges (IEDs)”, “(Multi)focal interictal epileptiform discharges (IEDs)”, “IEDs plus focal slowing” and “Normal” (including vigilance-related slowing or physiologic EEG). “IEDs plus focal slowing” and “Normal” (including vigilance-related slowing or physiologic EEG). For semiology comparison between migraine attacks and SeLEAS seizures, relevant information from physicians' letters was extracted, focusing on patients with confirmed diagnoses. The following symptoms were analyzed:Seizures during wakefulness and/or sleep.Emetic triad (nausea, retching, vomiting).Photophobia.Phonophobia.Gaze deviation.Visual disturbances.Other autonomic or additional symptoms (paleness, abdominal pain, urinary incontinence, dizziness, fatigue, silence). Seizures during wakefulness and/or sleep. Seizures during wakefulness and/or sleep. Emetic triad (nausea, retching, vomiting). Emetic triad (nausea, retching, vomiting). Photophobia. Photophobia. Phonophobia. Phonophobia. Gaze deviation. Gaze deviation. Visual disturbances. Visual disturbances. Other autonomic or additional symptoms (paleness, abdominal pain, urinary incontinence, dizziness, fatigue, silence). Other autonomic or additional symptoms (paleness, abdominal pain, urinary incontinence, dizziness, fatigue, silence). Due to limited case numbers, the Fisher´s exact test was used to assess the significance of differences in symptom frequency, with a significance threshold set at p < 0.05. Standard Protocol Approvals, Registrations, and Patient Consents This study was approved by the Ethics Committee of the University Medical Center Göttingen (file no. 20/7/21). Participant consent was not required for this retrospective observational study. Data Availability Data sets generated and analyzed during this study are not available as they contain confidential patient information. Results Between January 1, 2019, and December 31, 2020, a total of 4,430 EEGs were recorded at the Department of Pediatrics and Adolescent Medicine at the University Medical Center Göttingen. Of these, 186 patients aged 3 to 14 years underwent EEG as part of their initial outpatient presentation at the pediatric neurology consultation due to a referral diagnosis of “migraine” or “headache.” These patients constitute the cohort of this study. Patient Characteristics The sex distribution was nearly balanced, with 98 women (52.7%) and 88 men (47.3%). The average age at first presentation was approximately 11 years (10 years and 11 months), ranging from 3 years and 7 months to 14 years and 11 months. EEG Findings Of the 186 patients, 38 (20.4%) showed (multi) focal interictal epileptiform discharges (IEDs) in their initial EEG. In 4 patients (2.2%), focal slowing was also observed alongside IEDs. The majority, 144 patients (77.4%), had unremarkable EEGs. Diagnostic Assessment and Treatment Approach A flowchart (Figure) illustrates the diagnostic and therapeutic pathways. Based on clinical history, neurologic examination, and EEG findings, the diagnosis of SeLEAS was definitely established or considered probable in 19 of the 38 patients with IEDs. The remaining 19 patients, despite EEG findings of IEDs, were diagnosed with “migraine” (n = 11), “mixed migraine and tension-type headache (TTH)” (n = 2), or “TTH” (n = 5), according to the diagnostic criteria of the International Classification of Headache Disorders, third edition by their physicians. One patient with IEDs received a diagnosis of secondary headache. Notably, 4 patients with both IEDs and focal slowing were also diagnosed with “migraine,” “mixed migraine and TTH,” or “TTH”. Flowchart of the Diagnostic and Therapeutic Pathways ASM = antiseizure medication; IED = interictal epileptiform discharges; SeLEAS = self-limited epilepsy with autonomic seizures; TTH = tension type headache. Among the 19 patients initially diagnosed with SeLEAS, 17 were recommended to start prophylactic ASM due to their frequent, long-lasting, and stressful headache attacks with additional symptoms. This recommendation was discussed with the families. Of these 17, 15 patients initiated pharmacotherapy—14 with sulthiame (STM) (dosage between 3 and 5 mg/kg body weight/day, within the lower recommended range) and 1 with ethosuximide. All 15 patients who started medication attended follow-up appointments in pediatric neurology 3 to 6 months later. Of the 15 patients who started ASM, 12 (80%) experienced a significant improvement in their symptoms, 1 (6.7%) experienced worsening, and 2 (13.3%) reported no change. For the 3 patients who did not improve, neither the medication type nor the dose was changed; later, their diagnosis was revised to “migraine,” and they were treated with magnesium. Interestingly, 2 of these 3 patients reported an improvement in attacks after taking magnesium. In addition, 1 patient who responded well to STM noted that headaches increased if the medication was missed in the morning but improved again once taken. In total, 16 children and adolescents (8.6%) were finally diagnosed with SeLEAS. Among these, 12 (75%) showed clear symptom improvement with ASM, supporting the diagnosis, and we designate these 12 subjects as having “definite SeLEAS.” In 4 of the 19 patients initially diagnosed as having SeLEAS, ASM was either not recommended by the physician or not started by the family. Thus, no statement can be made about a possible improvement in symptoms after ASM. We designate these 4 subjects as having “probable SeLEAS.” In 3 of these 19 cases with initial diagnosis of SeLEAS, the lack of improvement under ASM with only a single antiseizure substance led to a revision of the initial diagnosis from SeLEAS to migraine. Furthermore, in 16 patients with IEDs on EEG and a clinical history compatible with both migraine and SeLEAS, the differential diagnosis of SeLEAS was not discussed with the families, and a therapeutic trial with ASM was not recommended during the consultation. We designate these 19 subjects (3 plus 16) as having “possible SeLEAS.” Most patients, 162 (87.1%), were finally diagnosed with migraine (n = 80), TTH (n = 60), or mixed migraine and TTH (n = 22). Among the 102 patients finally diagnosed as migraine or mixed migraine and TTH, only 83 had a normal EEG. IEDs were found in 19 (18.6%) of these subjects and in 6 (10%) of the patients with TTH. Finally, 8 patients (4.3%) were diagnosed with secondary headaches caused by underlying conditions such as sinusitis, orthostatic dysregulation, or pineal cyst. Comparison of Paroxysmal Symptoms in SeLEAS and Migraine Patients The paroxysmal symptoms reported by patients and their parents and documented in the physicians' letters were compared between 2 groups: those with a confirmed diagnosis of SeLEAS (based on response to ASM, n = 12) and those diagnosed with migraine and normal EEG (n = 65). The Fisher´s exact test (p ≤ 0.05) was used to determine whether the frequency of specific symptoms differed significantly between the groups. A supplementary eTable displays the results. In 6 of the 12 patients with SeLEAS, ictal headaches occurred both during wakefulness and sleep. Two patients (16.7%) experienced seizures exclusively during sleep, while 4 (33.3%) had seizures only when awake. By contrast, most patients with migraine (n = 38; 58.5%) reported attacks occurring only during wakefulness. In 6 patients with migraine (9.2%), attacks occurred both during sleep and when awake. For 33.8% (n = 22) of the migraine patients, medical records did not provide corresponding data. The Fisher´s exact test revealed that attacks occurring during sleep were significantly more common in SeLEAS patients than in those with migraine (p = 0.0007). The comparison of all other paroxysmal symptoms, including nausea, retching, vomiting, photophobia, phonophobia, visual disturbances, as well as a family history of migraine or epilepsy, revealed no statistic significant difference between the SeLEAS and the migraine patients. Discussion This retrospective observational study identified that 18.8% (n = 35) of pediatric patients referred to a tertiary pediatric neurology center for “migraine” or “headache” had a possible, probable, or definite diagnosis of self-limited epilepsy with autonomic seizures (SeLEAS, formerly known as Panayiotopoulos syndrome). A definite diagnosis of SeLEAS was established in 6.5% (n = 12) of these subjects, based not only on clinical history and EEG findings but additionally on a clear response to ASM. Furthermore, 3 other patients with features consistent with SeLEAS did not show improvement after a trial of a single ASM; however, this does not exclude the possibility of epilepsy. In addition, 12.4% (n = 23) of children and adolescents presenting with headache fulfilled the clinical and EEG criteria for SeLEAS but did not receive ASM, either because they were not diagnosed with epilepsy during the consultation (n = 19), or because the medication was not recommended by the physician or not initiated by the family (n = 4). Moreover, those “migraine” patients who experienced headache attacks during sleep (n = 6) may represent additional cases of SeLEAS, although their EEGs were normal. Of note, IEDs were found in 18.8% (n = 15) of the 80 patients with a final diagnosis of migraine, but in only 10% (n = 6) of the 60 patients with TTH. Although this difference is not statistically significant (p = 0.23, Fisher´s exact test), it still points to the possibility of further SeLEAS patients in the migraine group. Previous reports have repeatedly emphasized that it is not possible to reliably differentiate between migraine and autonomic seizures based solely on the patient's history, including the semiology of the attacks such as headache and associated symptoms. As Koutroumanidis10 stated in 2002: “Diagnosis of Panayiotopoulos syndrome may be easily missed—mild and brief ictal autonomic symptoms in the presence of clear consciousness would suggest trivial nonepileptic conditions such as atypical migraine, gastroenteritis, or syncope.” In this study, a statistical comparison of seizure symptoms in SeLEAS patients vs attack symptoms in migraine patients revealed that seizures occurring during sleep were significantly more frequent in SeLEAS patients than in migraine patients. All other recorded symptoms—such as nausea, retching, vomiting, photophobia, phonophobia, visual disturbances, and a family history of migraine or epilepsy—did not differ significantly in frequency or presentation between the 2 groups. Surprisingly, the recent ILAE classification and definition of epilepsy syndromes with onset in childhood does not mention headache in its section on SeLEAS, despite noting that “Autonomic features at onset may vary, but most frequently include retching, pallor, flushing, nausea, malaise, or abdominal pain.”13 As mentioned earlier, data on the frequency of headaches associated with SeLEAS seizures vary widely, ranging from 4.6% to 55%.14,15 In the assessment of paroxysmal events in children characterized by headache accompanied by nausea, retching, and vomiting, diagnostic accuracy may be compromised in 2 main ways. First, while interictal epileptic EEG discharges in adults are closely associated with the occurrence of clinical seizures, this correlation is much weaker in children before puberty. Epileptiform EEG discharges have been reported in 2.9%–6.5% of healthy children.23,24 In addition, nonepileptic conditions such as attention deficit hyperactivity disorder and autism spectrum disorders are well known to be associated with an increased frequency of epileptiform discharges.25 Second, epileptiform discharges may not be detectable in every EEG, especially when recorded during wakefulness in pediatric focal epilepsies, including epilepsy with autonomic seizures.8,14 Consequently, in ambiguous pediatric clinical phenotypes, epilepsy with autonomic seizures may remain undiagnosed if the EEG appears deceptively normal. Conversely, migraine may be misdiagnosed as epilepsy when EEG shows misleading epileptiform discharges. Furthermore, there are pathophysiologic overlaps between these conditions. Therefore, clinicians face considerable diagnostic uncertainty. Our findings provide new insights into the approach to both migraine and SeLEAS. Although migraine is the most common cause of headache attacks with nausea, retching, and vomiting, a significant subgroup of pediatric patients presenting these features may actually have an epileptic condition. Conversely, while seizures in SeLEAS are generally considered “infrequent in most patients, with only 25% experiencing a single seizure,”13 the subset of misdiagnosed “migraine” patients reported here had a long history of frequent, stressful headache attacks. Thus, recurrent autonomic seizures presenting with headache, nausea, retching, and vomiting—without impaired awareness—should be recognized as part of the clinical spectrum of SeLEAS. Our study ties in with earlier considerations regarding the complex relationship between headaches and epilepsy.26-31 It has been stressed that “headache as a symptom, with migraine characteristics and/or TTH characteristics, may be the only clinical ictal manifestation of an epileptic seizure.”31 This condition has been classified as “ictal epileptic headache.”26-31 Published criteria for “ictal epileptic headache” include a “headache/migraine attack as the sole clinical ictal symptom of epileptic origin, confirmed by ictal-EEG recording and clinical-EEG responsiveness to IV antiepileptic drugs.”31 In accordance with other authors, we do not advocate EEG as a routine examination for children diagnosed with headache, but agree that EEG “is mandatory and must be carried out promptly in cases of prolonged migraine/headache that does not respond to antimigraine drugs and in which epilepsy is suspected.”31 The retrospective design of our study presents both strengths and limitations. A notable strength is that we were able to include all pediatric patients up to 14 years of age who presented at a tertiary referral center for pediatric neurology with a diagnosis of “migraine” or “headache,” without selection bias. Such bias could potentially arise in prospective studies due to varying willingness of parents to participate, read, and sign informed consent forms. Therefore, our retrospective approach provides real-world data reflective of routine clinical practice. However, a clear limitation of our study is the inconsistent diagnostic and therapeutic approach among the assistant physicians, who rotate through consultation hours as part of their specialty training. This variability may have influenced diagnostic categorization and treatment recommendations. A prospective study with a standardized, uniform protocol would help mitigate these issues, ensuring more consistent data collection and management. Nonetheless, our study accurately reflects the real-life situation in a university pediatric neurology outpatient setting. Most patients in this study treated for SeLEAS received an ASM with STM. This drug was developed in the 1950s, introduced to the market in the 1960s, and is available in countries such as Argentina, Australia, the Czech Republic, Germany, Greece, Latvia, Hungary, Israel, Slovakia, and Switzerland.32 Although STM is not available for purchase in most Anglo-American countries, it is used very frequently in German-speaking regions due to its notably favorable ratio of seizure-inhibiting effectiveness to undesirable side effects, especially in SeLECTS.32 In addition, several studies have demonstrated the efficacy of STM in other genetic and structural focal epilepsies, particularly in children and adolescents.32 Like the antiepileptic drugs zonisamide and topiramate, STM is an inhibitor of mammalian carbonic anhydrase isoforms I-XIV.33 Zonisamide, in particular, is widely used in the preventive treatment of childhood and adolescent migraine.34 Although we did not find studies specifically examining the effect of STM on migraine, given its similar biochemical mechanism of action, we cannot exclude the possibility that STM may have improved migraine symptoms rather than SeLEAS in some individual patients enrolled in this study. However, this seems unlikely, as in the 12 patients who experienced headache improvement under STM, the effect was immediate and rapid, consistent with the seizure-inhibiting effects of STM observed in SeLECTS. Our study likely reflects the situation of thousands of pediatric patients worldwide with migrainoid headache attacks resistant to migraine medication who go undiagnosed with their benign epilepsy that is easy to treat. In the diagnostic workup of pediatric headache patients, clinicians—both pediatricians and pediatric neurologists—should give greater consideration to the differential diagnosis of SeLEAS than in the past, especially due to its significant therapeutic implications. The diagnostic process should include a detailed medical history focusing on characteristic features of autonomic seizures, comprising headache attacks during sleep, ictal gaze deviation (which is rarely reported by eyewitnesses spontaneously), ictal nausea, retching and vomiting, as well as impaired consciousness. EEG should be part of clinical assessment in ambiguous phenotypes, preferably as an ictal recording. We are aware that our suggestion of including an EEG in the diagnostic assessment of a child with an ambiguous migraine-like phenotype of headache attacks may be perceived as quite unreasonable at first glance, given that international headache guidelines do not recommend an EEG in the diagnostic evaluation of childhood migraine. However, patients do not benefit from a strict separation of different areas of expertise; clinical neurology should always take all available aspects into account, and guidelines should be open for discussion when new aspects arise.TAKE-HOME POINTS→ Based on history alone, a childhood migraine may be indistinguishable from a seizure with autonomic features.→ Our retrospective observational study investigated the proportion of misdiagnoses in this context.→ Of 186 children referred for “migraine” or “headache”, 18.8% (n = 35) received a possible, probable, or definite diagnosis of self-limited epilepsy with autonomic seizures (SeLEAS).→ This diagnostic assignment was based on clinical history, EEG findings, and, for a definite diagnosis of SeLEAS in 6.5% (n = 12), on clear efficacy of antiseizure medication.→ EEG may help discerning migraine from epilepsy in ambiguous pediatric headache attacks. TAKE-HOME POINTS → Based on history alone, a childhood migraine may be indistinguishable from a seizure with autonomic features.→ Our retrospective observational study investigated the proportion of misdiagnoses in this context.→ Of 186 children referred for “migraine” or “headache”, 18.8% (n = 35) received a possible, probable, or definite diagnosis of self-limited epilepsy with autonomic seizures (SeLEAS).→ This diagnostic assignment was based on clinical history, EEG findings, and, for a definite diagnosis of SeLEAS in 6.5% (n = 12), on clear efficacy of antiseizure medication.→ EEG may help discerning migraine from epilepsy in ambiguous pediatric headache attacks. → Based on history alone, a childhood migraine may be indistinguishable from a seizure with autonomic features. → Based on history alone, a childhood migraine may be indistinguishable from a seizure with autonomic features. → Our retrospective observational study investigated the proportion of misdiagnoses in this context. → Our retrospective observational study investigated the proportion of misdiagnoses in this context. → Of 186 children referred for “migraine” or “headache”, 18.8% (n = 35) received a possible, probable, or definite diagnosis of self-limited epilepsy with autonomic seizures (SeLEAS). → Of 186 children referred for “migraine” or “headache”, 18.8% (n = 35) received a possible, probable, or definite diagnosis of self-limited epilepsy with autonomic seizures (SeLEAS). → This diagnostic assignment was based on clinical history, EEG findings, and, for a definite diagnosis of SeLEAS in 6.5% (n = 12), on clear efficacy of antiseizure medication. → This diagnostic assignment was based on clinical history, EEG findings, and, for a definite diagnosis of SeLEAS in 6.5% (n = 12), on clear efficacy of antiseizure medication. → EEG may help discerning migraine from epilepsy in ambiguous pediatric headache attacks. → EEG may help discerning migraine from epilepsy in ambiguous pediatric headache attacks.